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Material and Methods: 100 CT datasets of cervical cancer 
patients (stage IB2 – IIIB) receiving HDR application (50 
tandem-ovoid and 50 tandem-ring) were studied. The 
external beam radiotherapy dose was 50Gy. Brachytherapy 
was delivered using a CT-MRI compatible tandem-ovoid (50 
patients) and a tandem-ring applicator (50 patients) to a dose 
of 8Gy/# in 2fractions. Bladder and rectum were contoured 
using oncentra planning system. DVHs were calculated and 
D2cc was recorded for bladder and rectum and compared 
with the corresponding ICRU point doses. The point B dose, 
the treated volume, high dose volume and the treatment 
time was recorded and compared for the two applicators. 
 
Results: 
 
Applicator 
Mean 
D2cc 
Bladder 
(Gy) 
Mean 
ICRU 
Bladder 
(Gy) 
Mean 
D2cc 
Rectum 
(Gy) 
Mean 
ICRU 
rectum 
(Gy) 
ICRU/D2cc 
ratio 
Bladder 
ICRU/D2cc 
ratio 
Rectum 
Tandem-
Ring 6.57 5.56 3.95 5 0.847 1.265 
Tandem-
ovoid 7.30 5.63 4.79 5.65 0.772 1.179 
 
Conclusion: The results indicate that the OAR doses assessed 
by DVH criteria were higher than ICRU point doses for bladder 
with both tandem-ovoid and tandem-ring applicators whereas 
DVH based dose was lower than ICRU dose for rectum. The 
point B dose, the treated volume and high dose volume was 
found to be slightly higher with tandem-ovoid applicator 
whereas the total treatment time was higher with the 
tandem-ring applicator. The mean D2cc dose for bladder and 
rectum was lower with tandem-ring applicators. The clinical 
implication of the above dosimetric differences needs to be 
evaluated further. 
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Purpose or Objective: The aim of this study is to evaluate an 
accurate method to define vaginal dose distribution in the 
delivery of vaginal vault brachytherapy (VBT) utilising a 
single channel cylinder. 
 
Material and Methods: A retrospective analysis of all 3D 
single channel cylinder VBT plans held on BrachyVision™ 10.0 
treatment planning system obtained between April 2011 and 
December 2013. All patients received treatment to the top 
4cm of the vagina at 0.5cm depth prescription point with 
fractional doses of 5.5Gy or 7Gy. Dose assessment is 
conducted using both point dose values and DVH parameters 
for vaginal wall. A vaginal apex dose point (VAdp) was 
defined as a midline point on the single channel cylinder, 
positioned at the apex representing vaginal surface dose 
(Gy). A second rectal / vaginal dose point (RVdp), positioned 
0.5cm posterior to vaginal wall (ICRU rectal point) is also 
used. This is potentially a good surrogate for vaginal mucosa 
dose due to its proximity to vaginal cylinder. A presumed 
vaginal wall thickness of 0.5cm was used to grow a volume 
representing the upper 4 cm of vaginal mucosa; the D2cc (Gy) 
and D5cc (Gy) are recorded. Pearson’s correlation coefficient 
is used to calculate correlation between dose point values 
and dose volume parameters obtained. A p-value <0.05 was 
considered statistically significant in this study. 
 
Results: A total of 113 CT data sets are analysed. 69% (n = 
78) of patients had a prescribed fractional dose of 5.5Gy and 
31% (n = 35) received 7Gy fractional dose. 
 
 
 
No correlation was identified between RVdp and D2cc for 
5.5Gy plans (r=0.004, p=0.974) and 7.0Gy plans (r=0.009, 
p=0.957). Similarly no correlation was identified between the 
RVdp and D5cc for 5.5Gy plans (r=0.170, p=0.138) and 7.0Gy 
plans (r=0.071, p=0.687). The D2cc showed a weak 
correlation with VAdp for 5.5Gy (r=0.200, p=0.083) and 7Gy 
plans (r=0.351, p=0.039); however only statistically 
significant with 7Gy plans. No relationship exists between 
VAdp and D5cc for 5.5Gy (r=0.146, p=0.202) and 7Gy plans 
(r=0.068, p=0.699).  
 
Conclusion: The RV dp is not a good surrogate for vaginal 
dosimetry. The VAdp could possibly be considered to predict 
D2cc values however dose volume parameters remain the 
accurate method when recording dose to vaginal mucosa 
from delivery of VBT. 
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Purpose or Objective: The aim of this study is to establish 
whether one initial CT planning scan for vaginal vault 
brachytherapy (VBT) patients is adequate to ensure 
surrounding OAR (bladder, rectum, sigmoid colon and small 
bowel) do not breach their dose constraints, or whether 
patients should be CT planned before each VBT fraction due 
to variations in OAR volumes and organ movement. 
 
Material and Methods: Patients were scanned twice with a 
segmented single central channel vaginal cylinder in situ. The 
first CT scan (A) was carried out, as per departmental 
protocol, two weeks prior to treatment delivery and the 
subsequent scan (B) on the first day of treatment. All 
patients were treated using scan A. OAR dose deviations were 
retrospectively calculated by applying the same dwell 
positions and loadings to scan B. The total EQD2 OAR dose 
received by VBT and EBRT was then assessed for tolerance 
breach (bladder 80Gy; rectum, sigmoid colon and small bowel 
70Gy). Both scans were analysed using Pearson correlation 
coefficient to determine relationships between % differences 
of OAR volumes and the OAR D2cc dose % differences. 
Additional bladder, rectum and GI structure (sigmoid colon 
and small bowel) contours were created combining the two 
scans (A+B); to simulate the worst case scenario structure 
movement between treatments. 
 
Results: 42 patients were scanned twice in total. 5 patients 
were prescribed 21Gy in 3 fractions after 45Gy in 25 fractions 
EBRT, 27 patients were prescribed 11Gy in 2 fractions after 
45Gy in 25 fractions EBRT and 10 patients were prescribed 
21Gy in 3 fractions of VBT only. Scan B CT plans showed all 
patients receiving VBT only or EBRT with 2 fractions of VBT 
had total EQD2 doses within published OAR dose tolerances. 4 
out of 5 (80%) patients treated with EBRT and 21Gy of VBT 
exceeded at least one OAR dose tolerance and when contours 
were combined 100% of these patients exceeded at least one 
